PharmChem, Inc. Announces Exploration of Strategic Alternatives
PharmChem (OTC: PCHM), a leading provider of sweat patches for drug abuse detection, announced on February 3, 2025, that its Board of Directors has initiated an exploration of strategic alternatives. The company will consider various options including acquisitions, potential sale, merger, or a debt-financed special dividend.
The Board believes PharmChem would be more valuable as part of a larger company and better positioned to serve customers. The company has established a data room for interested parties but has not retained a financial advisor, citing the Board's sufficient experience to guide the process.
The company emphasized there is no guarantee this review will result in any transaction or strategic outcome, and no specific timeline has been set. Further announcements will only be made if the Board approves a specific transaction or if disclosure is legally required.
PharmChem (OTC: PCHM), un fornitore leader di cerotti per il rilevamento dell'abuso di sostanze, ha annunciato il 3 febbraio 2025 che il suo Consiglio di Amministrazione ha avviato un'esplorazione di alternative strategiche. L'azienda prenderà in considerazione diverse opzioni, tra cui acquisizioni, possibile vendita, fusione o un dividendo straordinario finanziato attraverso indebitamento.
Il Consiglio crede che PharmChem sarebbe più preziosa come parte di una società più grande e meglio posizionata per servire i clienti. L'azienda ha istituito una sala dati per le parti interessate, ma non ha nominato un consulente finanziario, citando l'esperienza sufficiente del Consiglio per guidare il processo.
L'azienda ha sottolineato che non c'è alcuna garanzia che questa revisione porterà a una transazione o a un risultato strategico e non è stato fissato alcun termine specifico. Ulteriori annunci saranno effettuati solo se il Consiglio approverà una transazione specifica o se la divulgazione sarà legalmente richiesta.
PharmChem (OTC: PCHM), un proveedor líder de parches para la detección de abuso de drogas, anunció el 3 de febrero de 2025 que su Junta Directiva ha iniciado una exploración de alternativas estratégicas. La empresa considerará varias opciones, incluyendo adquisiciones, posible venta, fusión o un dividendo especial financiado por deuda.
La Junta cree que PharmChem tendría más valor como parte de una empresa más grande y estaría mejor posicionada para servir a los clientes. La compañía ha establecido una sala de datos para las partes interesadas, pero no ha contratado un asesor financiero, citando la experiencia suficiente de la Junta para guiar el proceso.
La empresa enfatizó que no hay garantía de que esta revisión resultará en alguna transacción o resultado estratégico, y no se ha establecido un cronograma específico. Se harán más anuncios solo si la Junta aprueba una transacción específica o si la divulgación es legalmente requerida.
PharmChem (OTC: PCHM), 약물 남용 탐지를 위한 스웨트 패치의 선두 제공업체, 2025년 2월 3일 이사회의 전략적 대안 탐색을 시작했다고 발표했습니다. 회사는 인수, 잠재적 판매, 합병 또는 부채로 자금을 조달한 특별 배당금을 포함한 여러 옵션을 고려할 것입니다.
이사회는 PharmChem이 더 큰 회사의 일부로서 더 큰 가치를 지닐 것이며 고객을 더 잘 지원할 수 있을 것이라고 믿고 있습니다. 회사는 관심 있는 당사자를 위한 데이터 룸을 마련했지만, 이사회가 프로세스를 안내할 수 있는 충분한 경험이 있다며 재정 고문을 retained하지 않았습니다.
회사는 이 검토가 어떤 거래나 전략적 결과를 초래할 것이라는 보장이 없으며, 특정 일정이 설정되지 않았다고 강조했습니다. 이사회가 특정 거래를 승인하거나 법적 요구 사항이 있는 경우에만 추가 발표가 있을 것입니다.
PharmChem (OTC: PCHM), un fournisseur leader de patchs de transpiration pour la détection de l'abus de drogues, a annoncé le 3 février 2025 que son Conseil d'Administration avait lancé une exploration d'alternatives stratégiques. L'entreprise envisagera diverses options, y compris des acquisitions, une vente potentielle, une fusion ou un dividende exceptionnel financé par la dette.
Le Conseil croit que PharmChem serait plus précieuse en tant que partie d'une plus grande entreprise et mieux positionnée pour servir ses clients. L'entreprise a établi une salle de données pour les parties intéressées, mais n'a pas retenu de conseiller financier, citant l'expérience suffisante du Conseil pour guider le processus.
L'entreprise a souligné qu'il n'y a aucune garantie que cette révision aboutisse à une transaction ou à un résultat stratégique, et aucun calendrier spécifique n'a été fixé. D'autres annonces ne seront faites que si le Conseil approuve une transaction spécifique ou si une divulgation est légalement requise.
PharmChem (OTC: PCHM), ein führender Anbieter von Schweißpflastern zur Erkennung von Drogenmissbrauch, gab am 3. Februar 2025 bekannt, dass der Vorstand eine Untersuchung strategischer Alternativen eingeleitet hat. Das Unternehmen wird verschiedene Optionen in Betracht ziehen, darunter Akquisitionen, möglichen Verkauf, Fusion oder eine schuldenfinanzierte Sonderdividende.
Der Vorstand ist der Ansicht, dass PharmChem als Teil eines größeren Unternehmens wertvoller und besser in der Lage wäre, die Kunden zu bedienen. Das Unternehmen hat einen Datenraum für interessierte Parteien eingerichtet, aber keinen Finanzberater beauftragt, da der Vorstand über ausreichende Erfahrung verfügt, um den Prozess zu leiten.
Das Unternehmen betonte, dass es keine Garantie gibt, dass diese Überprüfung zu einer Transaktion oder strategischen Ergebnis führt, und es wurde kein spezifischer Zeitrahmen festgelegt. Weitere Ankündigungen werden nur gemacht, wenn der Vorstand eine spezifische Transaktion genehmigt oder wenn eine Offenlegung gesetzlich erforderlich ist.
- Company holds leading position in sweat patch drug detection market
- Board's confidence in company's market positioning and value potential
- Multiple strategic options under consideration including potential sale or merger
- No financial advisor retained for the strategic review process
- Uncertainty about timeline and outcome of strategic review
- Possible debt increase if special dividend option is chosen
The Company has not retained a financial advisor at this time based on its belief that the Board's experience and expertise can guide the company through the process. The Company will consider various options, including acquisitions, potential sale of the Company, merger, or a debt financed special dividend. The Company has set up a data room for interested parties.
The Board believes the Company and its products are well positioned in the industry and that the Company would be more valuable as part of a larger company than as a stand-alone entity, and also be better able to serve its customers. There can be no assurance that the review being undertaken will result in a merger, tender offer, sale or other business combination involving the Company, or a special dividend. There is no deadline or definitive timetable set for completion of the strategic alternatives review process and there can be no assurance that this process will result in the Company pursuing a transaction or any other strategic outcome. The Company does not intend to make further announcements regarding the review unless and until the Board has approved a specific transaction or other course of action requiring disclosure, or the Company determines that a disclosure is required by law or otherwise deemed appropriate.
If interested parties have further, specific questions, please email our CFO Shana Veale at sveale@pharmchem.com and we will set up a call.
Tim Eriksen
Chairman of the Board
About PharmChem, Inc.
PharmChem, Inc. ("PharmChem") (OTC: PCHM), headquartered in
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This letter contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933 ("Forward-looking Statements"), which are subject to the "safe harbor" created by these Sections. Forward-looking statements are statements about future financial results, future products or services and other events that have not yet occurred. These forward-looking statements contain words such as, but not limited to, "expect," "anticipate," "estimate," "believe," "will," "may" or "might." Forward-looking statements are not historical facts, but instead represent only the Company's beliefs regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results, financial condition and developments may differ, possibly materially, from the anticipated results, developments and financial condition indicated in these forward-looking statements. Management believes that these forward-looking statements are reasonable as of the time made. However, caution should be taken not to place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. Our Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from our Company's historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, whether the objectives of the strategic alternative review process will be achieved; the terms, structure, benefits and costs of any strategic transaction; the timing of any transaction and whether any transaction will be consummated at all; the risk that the strategic alternatives review and its announcement could have an adverse effect on the ability of the Company to retain customers and retain and hire key personnel and maintain relationships with customers, suppliers, employees, shareholders and other business relationships; the risk the strategic alternatives review could divert the attention and time of the Company's management' and the risk of any unexpected costs or expenses resulting from the review.
View original content to download multimedia:https://www.prnewswire.com/news-releases/pharmchem-inc-announces-exploration-of-strategic-alternatives-302366396.html
SOURCE PharmChem, Inc.
FAQ
What strategic alternatives is PharmChem (PCHM) considering in February 2025?
Why hasn't PharmChem (PCHM) hired a financial advisor for its strategic review?
What is the timeline for PharmChem's (PCHM) strategic alternatives review?
How will PharmChem (PCHM) communicate updates about the strategic review process?
What is PharmChem's (PCHM) current market position in drug detection?
